Samsung Biologics Sees Biosimilars As One Of Three Key Pillars

Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen

 
• By David Wallace
  
Three Stone Pillars Structure Rome
CDMO, biosimilars and new drugs are the three key business areas for Samsung Biologics • Source: Arturas Jasevicius / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business